Monte Rosa Therapeutics, Inc. (GLUE)

NASDAQ: GLUE · IEX Real-Time Price · USD
11.62
+0.01 (0.09%)
Jul 7, 2022 10:23 AM EDT - Market open

Income Statement (Trailing)

Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Quarter Ending 2022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
Selling, General & Admin
19.8815.7312.548.75.764.01---0.64
Research & Development
65.857.1648.8939.2529.4624.01---7.35
Operating Expenses
85.6872.8861.4347.9535.2228.01---7.99
Operating Income
-85.68-72.88-61.43-47.95-35.22-28.01----7.99
Interest Expense / Income
000000----0
Other Expense / Income
-0.071.088.748.958.637.87000-0.25
Pretax Income
-85.61-73.96-70.17-56.9-43.85-35.88000-7.74
Net Income
-85.61-73.96-70.17-56.9-43.85-35.88----7.74
Net Income Common
-85.61-73.96-70.17-56.9-43.85-35.88----7.74
Shares Outstanding (Basic)
4725465222115
Shares Outstanding (Diluted)
472546522---5
Shares Change
2626.13%1548.09%----69.66%----
EPS (Basic)
-4.68-2.96-23.88-27.74-27.75-23.65----1.55
EPS (Diluted)
-4.68-2.96-23.88-27.74-27.75-23.65----1.55
Free Cash Flow Per Share
-1.76-2.76-1.34-9.84-22.87-17.43----1.51
EBITDA
-82.62-71.83-68.63-55.76-43.11-35.34----7.67
Depreciation & Amortization
2.992.131.551.140.740.54---0.07
EBIT
-85.61-73.96-70.17-56.9-43.85-35.88----7.74
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).